Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Bone marrow transplant

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44346   clinical trials with a EudraCT protocol, of which   7374   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    432 result(s) found for: Bone marrow transplant. Displaying page 12 of 22.
    «« First « Previous 8  9  10  11  12  13  14  15  16  Next» Last»»
    EudraCT Number: 2004-003845-41 Sponsor Protocol Number: UCL/07/131 Start Date*: 2009-02-06
    Sponsor Name:University College London
    Full Title: Transplantation of umbilical cord blood (UCB) from unrelated donors (URD) in patients with haematological diseases using a reduced intensity conditioning regimen.
    Medical condition: Haematological disorders
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004851 10018847 Haematological disorders HLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-002680-26 Sponsor Protocol Number: RP-L201-0218 Start Date*: 2018-11-27
    Sponsor Name:Rocket Pharmaceuticals, Inc.
    Full Title: Gene Therapy for Leukocyte Adhesion Deficiency-I (LAD-I): A Phase I Clinical Trial to Evaluate the Safety and Efficacy of the Infusion of Autologous Hematopoietic Stem Cells Transduced with a Lenti...
    Medical condition: Leukocyte Adhesion Deficiency-I (LAD-I)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10018137 Genetic anomalies of leukocytes LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-004356-16 Sponsor Protocol Number: D8850C00002 Start Date*: 2020-11-18
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase III Randomized, Double-blind, Placebo-controlled, Multi-center Study in Adults to Determine the Safety and Efficacy of AZD7442, a Combination Product of Two Monoclonal Antibodies (AZD8895 a...
    Medical condition: COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2019-000911-10 Sponsor Protocol Number: PHINK_01_2019 Start Date*: 2020-09-16
    Sponsor Name:Fundacion de investigacion Biomedica Hospital Universitario la Paz (FIBHULP)
    Full Title: A phase I dose-scalation multicentre study to evaluate the safety of a single infusion of alloreactive or IL-15 ex-vivo activated Natural Killer cells after Haploidentical Stem Cell Transplantation...
    Medical condition: High risk leukaemia paediatric patients who would receive an haploidentical HSCT to be cured
    Disease:
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Temporarily Halted)
    Trial results: (No results available)
    EudraCT Number: 2005-000679-16 Sponsor Protocol Number: EORTC 06023 Start Date*: 2005-05-17
    Sponsor Name:European Organisation for Research and Treatment of Cancer
    Full Title: Randomized phase II trial with infliximab (Remicade) in patients with myelodysplastic syndrome and a relatively low risk of developing acute leukemia
    Medical condition: myelodysplastic syndrome (MDS)
    Disease: Version SOC Term Classification Code Term Level
    7.1 10028533 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2021-000705-25 Sponsor Protocol Number: AT148002 Start Date*: 2021-06-09
    Sponsor Name:ALX Oncology Inc.
    Full Title: A PHASE 1/2 STUDY OF ALX148 IN COMBINATION WITH AZACITIDINE IN PATIENTS WITH HIGHER RISK MYELODYSPLASTIC SYNDROME (MDS) (ASPEN-02)
    Medical condition: Patients with higher risk myelodysplastic syndrome (MDS) who have not yet been treated for their disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028533 Myelodysplastic syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) ES (Ongoing) BE (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-001757-16 Sponsor Protocol Number: DSMMXV Start Date*: 2016-11-17
    Sponsor Name:GWT-TUD GmbH
    Full Title: Pomalidomide, ixazomib, and dexamethasone (PId) with or without intensification by cyclophosphamide (PICd): A phase II study in relapsed or refractory multiple myeloma
    Medical condition: Relapsed/refractory multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067095 Multiple myeloma progression LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-005491-41 Sponsor Protocol Number: B1931022 Start Date*: 2012-06-13
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: An Open-label, Randomized Phase 3 Study of Inotuzumab Ozogamicin Compared to a Defined Investigator’s Choice in Adult Patients with Relapsed or Refractory CD22-Positive Acute Lymphoblastic Leukemia...
    Medical condition: Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) SK (Completed) SE (Completed) ES (Completed) GB (Completed) DE (Completed) FI (Completed) IT (Completed) NL (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2021-000541-41 Sponsor Protocol Number: N/A Start Date*: 2021-04-22
    Sponsor Name:Oslo University Hospital
    Full Title: European DisCoVeRy for Solidarity: An Adaptive Pandemic and Emerging Infection Platform Trial
    Medical condition: SARS-CoV-2- infection
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004862 10084401 COVID-19 respiratory infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned) BE (Trial now transitioned) DE (Trial now transitioned) HU (Trial now transitioned) SK (Trial now transitioned) IE (Trial now transitioned) PT (Trial now transitioned) CZ (Trial now transitioned) ES (Ongoing) FR (Trial now transitioned) AT (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-004529-41 Sponsor Protocol Number: RV-MM-GITMO-413 Start Date*: 2008-09-04
    Sponsor Name:FONDAZIONE NEOPLASIE SANGUE ONLUS
    Full Title: Safety And Efficacy Of Lenalidomide As Maintenance Therapy In Patients With Newly Diagnosed Multiple Myeloma Following A Tandem Autologous-Allogeneic Transplant
    Medical condition: Patients With Newly Diagnosed Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028228 Multiple myeloma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-012417-22 Sponsor Protocol Number: CTKI258A2204 Start Date*: 2010-04-29
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase II, multi-center, non-randomized, open-label study of TKI258 in patients with relapsed or refractory multiple myeloma, who are with or without t(4;14) translocation
    Medical condition: Patients with relapsed or refractory multiple myeloma, who are with or without t(4;14) translocation
    Disease: Version SOC Term Classification Code Term Level
    12.1 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) FR (Completed) DE (Completed) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-001671-51 Sponsor Protocol Number: SGN35-023 Start Date*: 2016-06-15
    Sponsor Name:Seattle Genetics, Inc.
    Full Title: A RANDOMIZED, OPEN LABEL, PHASE 2 STUDY OF RITUXIMAB AND BENDAMUSTINE WITH OR WITHOUT BRENTUXIMAB VEDOTIN FOR RELAPSED OR REFRACTORY CD30-POSITIVE DIFFUSE LARGE B CELL LYMPHOMA
    Medical condition: i) Relapsed or Refractory CD30-Positive Diffuse Large B-Cell Lymphoma ii) follicular non-Hodgkin lymphoma (NHL) grade 3b
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012822 Diffuse large B-cell lymphoma refractory PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067070 Follicular B-cell non-Hodgkin's lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) CZ (Completed) FR (Completed) ES (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2020-004768-24 Sponsor Protocol Number: UCART22_01 Start Date*: 2021-12-06
    Sponsor Name:CELLECTIS SA
    Full Title: Open label dose-escalation and dose-expansion study to evaluate the safety, expansion, persistence and clinical activity of UCART22 (allogeneic engineered T-cells expressing anti-CD22 Chimeric Anti...
    Medical condition: Acute Lymphoblastic Leukaemia.
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000844 Acute lymphoblastic leukaemia LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-002584-70 Sponsor Protocol Number: 155-CL-009 Start Date*: 2007-09-14
    Sponsor Name:Astellas Pharma US, Inc.
    Full Title: A Phase II Multicenter, Open-Label Study of YM155 in Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Subjects
    Medical condition: Diffuse large B-cell Lymphoma refractory
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012822 Diffuse large B-cell lymphoma refractory PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) ES (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-002253-30 Sponsor Protocol Number: INCB39110-120 Start Date*: 2019-07-01
    Sponsor Name:Incyte Corporation
    Full Title: An Open-Label, Single-Arm, Phase 1/2 Study Evaluating the Safety and Efficacy of Itacitinib in Combination With Corticosteroids for the Treatment of Steroid-Naive Acute Graft-Versus-Host Disease in...
    Medical condition: Male or female, 28 days to less than 18 years of age, who have received an allogeneic hematopoietic stem cell transplant (allo-HSCT) and have developed Grade II to IV acute GVHD
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021428 - Immune system disorders 10066260 Acute graft versus host disease PT
    20.1 10021428 - Immune system disorders 10066262 Acute graft versus host disease in skin PT
    20.1 10021428 - Immune system disorders 10066264 Acute graft versus host disease in intestine PT
    20.1 10021428 - Immune system disorders 10066263 Acute graft versus host disease in liver PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) FR (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-001360-19 Sponsor Protocol Number: ADN011 Start Date*: 2016-01-04
    Sponsor Name:ADIENNE SA
    Full Title: Prospective, phase II/III, randomized clinical study to compare BEGEDINA® versus “conventional treatment” for treating steroid resistant acute graft-versus host disease
    Medical condition: steroid resistant acute graft versus host disease
    Disease: Version SOC Term Classification Code Term Level
    18.0 10021428 - Immune system disorders 10066260 Acute graft versus host disease PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) GB (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-000894-22 Sponsor Protocol Number: MAGIC-HR-ECP Start Date*: 2019-12-10
    Sponsor Name:Department of Stem Cell Transplantation - University Medical Center Hamburg-Eppendorf
    Full Title: Phase II multicenter study of extracorporeal photopheresis with UvadexTM plus standard steroid treatment for high risk acute Graft-versus-Host Disease
    Medical condition: New onset high risk acute GvHD following allogeneic SCT
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004870 10018653 Graft-versus-host disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-013093-41 Sponsor Protocol Number: AC220-002 Start Date*: 2010-02-05
    Sponsor Name:Ambit Biosciences Corporation
    Full Title: A PHASE 2 OPEN-LABEL, AC220 MONOTHERAPY EFFICACY (ACE) STUDY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) WITH FLT3-ITD ACTIVATING MUTATIONS
    Medical condition: Acute Myeloid Leukemia
    Disease: Version SOC Term Classification Code Term Level
    12.0 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) ES (Completed) NL (Completed) PL (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-003604-39 Sponsor Protocol Number: MC-FludT.17/M Start Date*: 2014-04-11
    Sponsor Name:medac GmbH
    Full Title: Clinical phase II trial to describe the safety and efficacy of Treosulfan-based conditioning therapy prior to allogeneic haematopoietic stem cell transplantation in paediatric patients with haemato...
    Medical condition: Male and female children with haematologic malignant diseases as acute lymphoblastic leukaemias (ALL), acute myeloid leukaemias (AML), myelodysplastic syndromes (MDS) and juvenile myelomonocytic le...
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10054439 Juvenile chronic myelomonocytic leukemia LLT
    21.0 100000004864 10060355 Acute myeloid leukaemia in remission LLT
    21.0 100000004864 10028534 Myelodysplastic syndrome NOS LLT
    21.0 100000004864 10000844 Acute lymphoblastic leukaemia LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed) AT (Completed) CZ (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-001699-20 Sponsor Protocol Number: 042011 Start Date*: 2012-05-18
    Sponsor Name:St. Anna Kinderkrebsforschung, GmbH
    Full Title: LCH-IV International Collaborative Treatment Protocol for Children and Adolescents with LANGERHANS CELL HISTIOCYTOSIS
    Medical condition: Langerhans cell histiocytosis
    Disease:
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: AT (Trial now transitioned) BE (Trial now transitioned) NL (Trial now transitioned) DK (Trial now transitioned) NO (Trial now transitioned) IE (Trial now transitioned) IT (Trial now transitioned) SE (Trial now transitioned) CZ (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) GR (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 8  9  10  11  12  13  14  15  16  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jun 28 02:00:00 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA